A disintegrin and metalloprotease 33 (ADAM33) was the first gene for which association with asthma was discovered using positional cloning (1). The linkage analysis identified two peaks in the region 20p13; using a more stringent definition of asthma with airway hyper-responsiveness (AHR), the strength of the association increased, with further analysis confirming ADAM33 as the strongest signal (1). Expression studies confirmed that ADAM33 was expressed in lung fibroblasts and airway smooth muscle cells, providing evidence for its role in the pathogenesis of asthma through airway remodelling and AHR (1).

Results from more than 20 subsequent association studies in ethnically diverse populations have confirmed the association between ADAM33 and asthma, or related phenotypes (2,3). However, it is of note that there is a considerable heterogeneity between studies, with associations not being reported consistently across all single-nucleotide polymorphisms (SNPs). Furthermore, in different studies, the same genetic variants conferred either an increased risk or were protective (e.g. for SNP S2-rs528557, some studies reported increased risk of asthma with rare C allele (4–8), whilst others found the same association with common G allele (1,9,10)). However, not all studies replicated the associations (11–14), and some failed to demonstrate single SNP associations, but reported a haplotypic association (15,16). Several studies found significant associations between ADAM33 variants and lung function (7,9,17), whilst one failed to find such association (6).

There are several possible reasons for this heterogeneity (e.g. differences in phenotype definition, sample size, choice of SNPs etc.) (2). It is also plausible that other genes or regulatory interactions with tobacco smoke exposure

Keywords
ADAM33; asthma; asthma severity; children; chromosome 20p13; environmental tobacco smoke exposure; gene–environment interactions

Abstract
Background: We investigated the association between genetic variation in chromosomal region 20p13-p12 (ADAM33 and flanking genes ATRN, GFRalpha4, SIGLEC1 and HSPA12B) and asthma. Amongst asthmatics, we then investigated the association between genetic variants and asthma severity. We evaluated the effect of environmental tobacco smoke exposure in the context of genetic variants.

Methods: In a case-control study, we recruited 423 asthmatic children and 414 non-asthmatic controls (age 5–18 yrs). Amongst asthmatics, we measured lung function and extracted data on hospitalisation for asthma exacerbation from medical records. Early-life ETS exposure was assessed by questionnaire. We included 85 single-nucleotide polymorphisms (SNPs) in the analysis.

Results: Seventeen SNPs were significantly associated with asthma; one (rs41534847 in ADAM33) remained significant after correction for multiple testing. Thirty-six SNPs were significantly associated with lung function, of which 15 (six ATRN, three ADAM33, five SIGLEC1 and one HSPA12B) remained significant after correction. We observed a significant interaction between 23 SNPs and early-life ETS exposure in relation to lung function measures. For example, for rs512625 in ADAM33, there was significant interaction with ETS exposure in relation to hospitalisations ($p_{\text{het}} = 0.02$) and lung function ($p_{\text{het}} = 0.03$); G-allele homozygotes had a 9.15-fold [95% CI 2.28–36.89] higher risk of being hospitalized and had significantly poorer lung function if exposed to ETS, with no effect of ETS exposure amongst A-allele carriers.

Conclusion: We demonstrated several novel significant interactions between polymorphisms in 20p13-p12 and early-life ETS exposure with asthma presence and, amongst asthmatics, a significant association with the severity of their disease.
elements in the vicinity of ADAM33 may be responsible for the observed association; of note, eight of the 24 SNPs associated with asthma in the discovery study were in two of ADAM33’s flanking genes, glial cell line-derived neurotrophic factor family receptor alpha 4 (GFRA4) and sialic acid-binding Ig-like lectin 1 (SIGLEC1)(1).

The modifying effects by gene–gene or gene–environment interactions may also be important (18). For example, tobacco smoke exerts most of its effects locally in the lung and may induce or suppress expression of tissue-specific asthma susceptibility genes. Given the proposed role of ADAM33 in contributing to airway smooth muscle and vascular modelling and remodelling (19), it is plausible that there may be an interaction between genetic variants and tobacco smoke exposure in modifying asthma risk. Several studies have investigated this interaction; as with genetic studies, the results are heterogeneous. For example, one study reported a significant effect modification of ADAM33 polymorphisms by in utero environmental tobacco smoke (ETS) exposure on lung function and AHR in children (6), but another study did not detect any such interactions (7).

We aimed to investigate the association between genetic variation in chromosomal region 20p13-p12 (ADAM33 and flanking genes) and asthma; amongst asthmatic patients, we then investigated the association between asthma severity (assessed by hospital admissions with acute exacerbation and lung function) and genetic variants. The effect of ETS exposure on the risk of asthma and asthma severity in the context of genetic variants was also evaluated.

Methods

Study design and setting

We carried out this case–control study in the Department of Paediatrics, General Hospital Slavonski Brod, Croatia. The study was approved by the local ethics committee, and informed consent was obtained from all parents (and children when appropriate).

Participants

Cases

Children with asthma aged 5–18 yr were recruited from the paediatric asthma clinic if all of the following criteria were met: (i) physician-diagnosed asthma, (ii) asthma symptoms (wheeze, cough, or both) within the previous 12 months, and (iii) current use of antiasthma medication.

Controls

Children in the same age range without respiratory symptoms (confirmed by an interviewer-administered questionnaire) were randomly selected from patients with non-respiratory conditions attending other hospital departments (e.g. fracture clinic); social and environmental variables matched with the general population.

Cases and controls were not matched by gender and age.

Data sources/measurement

Hospital admission with acute asthma

Trained paediatrician extracted all data on hospital admissions due to acute asthma exacerbation from paper-based hospital medical records.

Lung function was assessed in asthmatic children using spirometry according to the ATS/ERS guidelines (20,21) to measure forced expiratory volume in one second (FEV₁) as a percentage of predictive values (22), FEV₁/forced vital capacity (FVC) ratio and forced expiratory flow when 50% of the FVC has been expired (FEF₅₀).

ETS exposure

ETS exposure in early life was ascertained using a validated questionnaire and defined as a positive answer to the question: ‘Did mother smoke during pregnancy?’

Genotyping

Gene and tagging SNP Selection

Haplotype-tagging SNPs were selected in the 20p13-p12 region for ADAM33 and its flanking genes (attractin [ATRN], GFRA4, SIGLEC1 and heat shock 70kD protein 12B [HSPA12B]), using GVS (http://gvs.gs.washington.edu/GVS), complemented by NCBI’s dbSNP (www.ncbi.nlm.nih.gov/projects/SNP) and Haploview (23), using LD-based tagSNP selection with a pairwise algorithm LDSelect (24), available in GVS and Haploview (Tagger). SNPs identified in populations of European descent with a minor allele frequency (MAF) ≥ 5% were included in the algorithm. We selected an LD threshold of r² = 0.8. TagSNPs from all generated bins were selected and genotyping performed using Sequenom® MassARRAY® iPLEX™ (25). Three functional SNPs (ATRN, rs17782078 and rs3886999 and SIGLEC1, rs6037651) were forced included. Details of the 124 genotyped SNPs (46 in ATRN, 6 in GFRA4, 37 in ADAM33, 27 in SIGLEC1 and 8 in HSPA12B) are presented in Tables E1–E5. Quality control (QC) procedures were then applied and redundant SNPs excluded (Online Supplement).

Statistical analysis

Statistical analysis was carried out using svs 7.2.3 (Golden Helix, Bozeman, MT, USA) and sss 19 (SPSS, Chicago, IN, USA). For SNPs showing a trend for association in additive model, dominant and recessive model were tested. For consistency, all analyses were performed using major allele as reference. Correction for multiple comparisons was carried out using the false discovery rate (FDR) method (26). Results are presented as p-values (uncorrected and FDR corrected), and odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of effect size.

We analysed the associations between genetic variants and asthma using χ² test and logistic regression. All analyses were adjusted for gender. Analysis of gene–environment interactions was carried out using appropriate multivariate regression models.
For quantitative outcomes (lung function), we used correlation/trend test, univariate linear regression and general linear model univariate one-way independent ANOVA. FEV₁ and FEV₁/FVC followed a normal distribution; results are expressed as mean and 95% CI. FEF50 followed a log-normal distribution and hence was subject to a log transformation; the results are expressed as geometric mean (GM). FEV₁/FVC and FEF₅₀ analyses were adjusted for age, gender and height.

**Results**

**Participants**

We approached 923 children (438 asthmatics, 485 controls), of whom 86 declined and 837 agreed to participate in the study (91%; 423 asthmatics, 414 controls); 824 participants provided blood for DNA (417 asthmatics and 407 controls). Demographic characteristics of the study population are presented in Table 1. There was a significant difference in gender between the groups (males, 58.6% vs. 43.1%, cases vs. controls, p < 0.001); subsequent analyses were therefore adjusted for gender. There was a small, but statistically significant difference in age between the groups (11.1 vs. 12.2 yr, cases vs. controls, p < 0.001), which was deemed unlikely to be relevant for the analysis. There were no differences between the groups in early-life ETS exposure, area of residence or position in sibship. Amongst children with asthma, 150 (36%) were admitted to hospital at least once with asthma exacerbation, and 53 (12.7%) were hospitalized two or more times. There was no association between early-life ETS exposure and hospital admissions for acute asthma.

Genotyping success rates were generally high (>95%); 26 SNPs with a success rate <90%, three SNPs which were monomorphic in our population and 10 SNPs in high LD with other SNPs (r² > 90%) were excluded (Online supplement). We included 85 SNPs in the final analysis (LD plots shown in Fig. E1).

**Association analysis**

**Asthma presence**

Seventeen SNPs were significantly associated with asthma (Table 2, Fig. 1). For one SNP (rs41534847 in ADAM33), this association remained significant after correction for multiple testing, and for two ADAM33 SNPs (rs2485700, rs7354032), there was a strong trend after correction for multiple testing (p = 0.08).

**Asthma severity**

*Hospital admission with acute asthma exacerbation.* Amongst children with asthma, G-allele homozygotes in rs512625 (ADAM33) and T-allele carriers in rs532448 (SIGLEC1) had increased risk for two or more hospital admissions compared with major allele homozygotes (OR [95% CI], 2.61 [1.10–6.17], p = 0.03 and 1.99 [1.04–3.81], p = 0.04, respectively).

Lung function. Thirty-six SNPs were significantly associated with different measures of lung function (Fig. 2, Table E6), of which 15 (six in ARTN, three in ADAM33, five in SIGLEC1 and one in HSPA12B) remained significant after correction for multiple testing (Table 3). For example, carriers of G allele of ARTN rs11696647 had significantly higher FEV₁ and FEF₅₀ than A-allele homozygotes (FDR p = 0.01). This SNP explained 6% of the variance in FEV₁. Carriers of minor allele on ADAM33 rs4987246 had significantly lower FEV₁ and FEF₅₀ than major allele homozygotes (FDR p < 0.03).

**Interaction between genetic variants and early-life ETS exposure**

**Asthma presence**

We observed significant interactions between six SNPs and early-life ETS exposure in relation to asthma (Table E7). For example, early-life ETS exposure significantly increased the risk of asthma amongst carriers of G allele on rs3848809 in ARTN (OR [95% CI], 2.09 [1.02–4.28], p = 0.04), but there was no effect of ETS exposure on asthma risk amongst A-allele homozygotes (0.91 [0.65–1.28], p = 0.6; Fig. E2).
Table 2 Association between genetic variants in 20p13-p12 and asthma

<table>
<thead>
<tr>
<th>SNP rs number</th>
<th>Gene</th>
<th>Alleles*</th>
<th>p-Value</th>
<th>FDR</th>
<th>Model</th>
<th>aOR</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS151518</td>
<td>ATRN</td>
<td>A/G</td>
<td>0.01</td>
<td>0.16</td>
<td>GG vs. GA+AA</td>
<td>2.22</td>
<td>1.21</td>
<td>4.07</td>
</tr>
<tr>
<td>RS2853224</td>
<td>ATRN</td>
<td>A/C</td>
<td>0.03</td>
<td>0.32</td>
<td>Additive</td>
<td>1.24</td>
<td>1.02</td>
<td>1.51</td>
</tr>
<tr>
<td>RS3848809</td>
<td>ATRN</td>
<td>A/G</td>
<td>0.02</td>
<td>0.27</td>
<td>GG vs. GA+AA</td>
<td>0.37</td>
<td>0.15</td>
<td>0.91</td>
</tr>
<tr>
<td>RS678963</td>
<td>ATRN</td>
<td>C/T</td>
<td>0.03</td>
<td>0.22</td>
<td>TT vs. TC +CC</td>
<td>1.76</td>
<td>1.06</td>
<td>2.93</td>
</tr>
<tr>
<td>RS677421</td>
<td>ATRN</td>
<td>A/T</td>
<td>0.02</td>
<td>0.47</td>
<td>TT+TA vs. AA</td>
<td>1.70</td>
<td>1.06</td>
<td>2.71</td>
</tr>
<tr>
<td>RS583688</td>
<td>ATRN</td>
<td>C/T</td>
<td>0.04</td>
<td>0.29</td>
<td>TT vs. TC +CC</td>
<td>1.49</td>
<td>1.01</td>
<td>2.19</td>
</tr>
<tr>
<td>RS235558</td>
<td>ATRN</td>
<td>A/G</td>
<td>0.02</td>
<td>0.21</td>
<td>GG vs. GA+AA</td>
<td>2.94</td>
<td>1.15</td>
<td>7.52</td>
</tr>
<tr>
<td>RS630909</td>
<td>GFRA4</td>
<td>A/G</td>
<td>0.03</td>
<td>0.23</td>
<td>GG vs. GA+AA</td>
<td>0.40</td>
<td>0.17</td>
<td>0.95</td>
</tr>
<tr>
<td>RS44707</td>
<td>ADAM33</td>
<td>A/C</td>
<td>0.02</td>
<td>0.22</td>
<td>CC vs. CA+ AA</td>
<td>1.56</td>
<td>1.06</td>
<td>2.31</td>
</tr>
<tr>
<td>RS41534847</td>
<td>ADAM33</td>
<td>C/T</td>
<td>&lt;0.01</td>
<td>0.04</td>
<td>TT+TC vs. CC</td>
<td>0.08</td>
<td>0.01</td>
<td>0.61</td>
</tr>
<tr>
<td>RS2485700</td>
<td>ADAM33</td>
<td>C/T</td>
<td>&lt;0.01</td>
<td>0.08</td>
<td>TT+TC vs. CC</td>
<td>1.68</td>
<td>1.19</td>
<td>2.36</td>
</tr>
<tr>
<td>RS511898</td>
<td>ADAM33</td>
<td>C/T</td>
<td>0.03</td>
<td>0.37</td>
<td>TT+TC vs. CC</td>
<td>1.37</td>
<td>1.04</td>
<td>1.82</td>
</tr>
<tr>
<td>RS3918392</td>
<td>ADAM33</td>
<td>A/G</td>
<td>0.03</td>
<td>0.41</td>
<td>GG+GA vs. AA</td>
<td>2.03</td>
<td>1.07</td>
<td>3.85</td>
</tr>
<tr>
<td>RS2787095</td>
<td>ADAM33</td>
<td>C/G</td>
<td>0.01</td>
<td>0.14</td>
<td>GG+GC vs. CC</td>
<td>1.50</td>
<td>1.12</td>
<td>2.01</td>
</tr>
<tr>
<td>RS487377</td>
<td>ADAM33</td>
<td>A/G</td>
<td>0.02</td>
<td>0.24</td>
<td>GG vs. GA+AA</td>
<td>2.19</td>
<td>1.09</td>
<td>4.43</td>
</tr>
<tr>
<td>RS7354032</td>
<td>ADAM33</td>
<td>C/T</td>
<td>&lt;0.01</td>
<td>0.08</td>
<td>TT+TC vs. CC</td>
<td>2.84</td>
<td>1.48</td>
<td>5.45</td>
</tr>
<tr>
<td>RS4813639</td>
<td>SIGLEC1</td>
<td>A/G</td>
<td>0.04</td>
<td>0.48</td>
<td>GG+GA vs. AA</td>
<td>1.46</td>
<td>1.02</td>
<td>2.11</td>
</tr>
</tbody>
</table>

All analyses are adjusted for gender.
Risk allele in bold type.
FDR, false discovery rate.
*Common allele is listed first/rare allele second.

Figure 1 Association between genetic variants in the region 20p13-p12 and asthma using the recessive (blue) and dominant (green) genetic models. The red line indicates significance.
Figure 2  Association between genetic variants in the region 20p13-p12 and lung function measures amongst asthmatic children; results of both dominant (blue) and recessive (green) models are shown. (a) FEV1% predicted. (b) FEV1/FVC ratio. (c) FEF50.
Hospital admission with acute asthma exacerbation

Amongst asthmatic children, we observed a significant interaction between rs512625 in \textit{ADAM33} and early-life ETS exposure in relation to hospital admissions ($p_{int} = 0.02$), in that homozygotes for G allele had higher risk of being hospitalized two or more times if they were exposed to ETS (OR [95% CI], 9.15 [2.28–36.89], $p = 0.002$), with no effect of ETS exposure amongst other genotype groups ($p = 0.8$).

Lung function

We observed a significant interaction between 23 SNPs in this region with early-life ETS exposure in relation to different lung function measures (Table E8). For example, the effect of early-life ETS exposure on FEF$_{50}$ differed between children with different genotypes in \textit{ADAM33} SNP rs512625, in that G-allele homozygotes had lower FEF$_{50}$ if they were exposed to ETS (GM [95% CI], 2.33 [1.79–2.51] vs. 3.16 [2.56–3.89], $p = 0.04$), with no effect of ETS exposure amongst carriers of A allele (2.82 [2.57–3.09] vs. 2.69 [2.60–2.82], exposed vs. non-exposed, $p = 0.52$; $p_{int} = 0.03$) (Fig. E3).

Discussion

Principal findings

To the best of our knowledge, our study is the first to demonstrate amongst asthmatic patients the association between polymorphisms in the 20p13-p12 region (\textit{ADAM33} and flanking genes) with different markers of asthma severity (hospital admissions with acute exacerbations and level of lung function) and a significant effect modification by early-life ETS exposure. We also confirmed the association between asthma presence and genetic variants in this region and a significant interaction with early-life ETS exposure in modifying asthma risk. One of these associations is novel (rs41534847 in \textit{ADAM33}) and remained significant after correction for multiple testing.

We found strong significant associations between 36 SNPs and lung function amongst asthmatics, 15 of which were still significantly associated after FDR correction. Most of these associations are novel (e.g. rs11696647, rs151518, rs2853224, rs678963, rs235515, rs618047, rs2853213, rs532448, rs656635, rs609203, rs3859664, rs4813636 and rs910652), whilst some had previously been reported (e.g. rs597980(17) and rs612709 (10)). The effect sizes appear higher than those reported by the majority of previous studies (e.g. SNP rs11696647 in \textit{ATRN} explained 6% of the variance in FEV$_1$). Amongst asthmatic patients, we identified genotypes which increased the risk of hospital admission due to acute exacerbations, which was further augmented by ETS exposure. For example, the risk of multiple hospitalisations was doubled amongst homozygotes for G allele in rs512625 (\textit{ADAM33}), with the magnitude of risk increasing further if they were exposed to ETS in early life (9-fold). Similar interaction between this genetic variant and ETS exposure was observed in relation to lung function.
Limitations and strengths

One of the limitations of the current study is that cases and controls were not matched by gender, and there was a preponderance of boys amongst cases. To address this, we adjusted all case-control analyses for gender. Lung function measurements were not available in the control children; lung function data amongst cases were used as a surrogate marker of asthma severity. We also acknowledge that ETS exposure was assessed by questionnaire rather than objective measurement (e.g. cotinine), which may underestimate the real exposure. We do not have data on the number of cigarettes smoked and could not assess whether there was any dose-response relationship with respect to ETS exposure.

Whilst the majority of previous replication studies focused on a limited number of selected polymorphisms in the region, we carried out a comprehensive investigation of known common variation within all five genes of interest (ADAM33, ATRN, GFRA4, SIGLEC1 and HSPA12B). Although we utilized all available data on common variation and LD within each gene to identify the lowest number of markers to capture most of the variation, we acknowledge the possibility that additional, as yet unknown, polymorphisms were not included. In addition, it is possible that SNPs other than those that we have identified may be the truly associated variants because of LD within the region.

Our study used a candidate gene approach, with a priori hypotheses on plausible associations between selected SNPs with asthma and asthma severity, and the interaction between genetic variants and ETS exposure. Although adjustment for multiple comparisons is therefore not essential, we used the FDR method (26) to adjust for total number of variants tested to increase the confidence that the results reflect true associations. For completeness, we present both uncorrected and corrected p-values, highlighting those that remained significant after correction as the most likely relevant associations.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Allele</th>
<th>FDR</th>
<th>Genotype</th>
<th>Mean (95% CI)</th>
<th>Genotype</th>
<th>Mean (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS11696647</td>
<td>ATRN</td>
<td>A/G</td>
<td>GG+GA</td>
<td>102.27 (99.76, 104.78)</td>
<td>GG+GA</td>
<td>3.06 (2.87, 3.26)</td>
</tr>
<tr>
<td>RS151518</td>
<td>ATRN</td>
<td>A/G</td>
<td>GG+GA</td>
<td>101.45 (99.16, 103.75)</td>
<td>GG+GA</td>
<td>2.78 (2.56, 3.03)</td>
</tr>
<tr>
<td>RS2853224</td>
<td>ATRN</td>
<td>A/C</td>
<td>CC+CA</td>
<td>100.26 (98.43, 102.1)</td>
<td>CC+CA</td>
<td>2.87 (2.74, 3.01)</td>
</tr>
<tr>
<td>RS678963</td>
<td>ATRN</td>
<td>C/T</td>
<td>AA</td>
<td>93.52 (90.55, 96.49)</td>
<td>AA</td>
<td>2.42 (2.25, 2.61)</td>
</tr>
<tr>
<td>RS235515</td>
<td>ATRN</td>
<td>C/G</td>
<td>GG+GC</td>
<td>101.59 (98.98, 104.2)</td>
<td>GG+GC</td>
<td>3.08 (2.88, 3.29)</td>
</tr>
<tr>
<td>RS618047</td>
<td>ATRN</td>
<td>A/G</td>
<td>GG+GA</td>
<td>100.32 (98.35, 102.3)</td>
<td>GG+GA</td>
<td>2.88 (2.74, 3.03)</td>
</tr>
<tr>
<td>RS44707(ST+4)</td>
<td>ADAM33</td>
<td>A/C</td>
<td>CC+CA</td>
<td>100.45 (98.47, 102.42)</td>
<td>CC+CA</td>
<td>2.49 (2.35, 2.64)</td>
</tr>
<tr>
<td>RS4987246</td>
<td>ADAM33</td>
<td>C/T</td>
<td>TT+TC</td>
<td>92.5 (86.16, 98.84)</td>
<td>TT+TC</td>
<td>2.98 (2.82, 3.14)</td>
</tr>
<tr>
<td>RS2853213</td>
<td>ADAM33</td>
<td>C/G</td>
<td>GG+GC</td>
<td>96.96 (94.96, 98.95)</td>
<td>GG+GC</td>
<td>2.49 (2.35, 2.64)</td>
</tr>
<tr>
<td>RS532448</td>
<td>SIGLEC1</td>
<td>A/T</td>
<td>TT+TA</td>
<td>96.55 (94.55, 98.55)</td>
<td>TT+TA</td>
<td>2.63 (2.5, 2.77)</td>
</tr>
<tr>
<td>RS656635</td>
<td>SIGLEC1</td>
<td>G/T</td>
<td>TT+TG</td>
<td>99.53 (97.74, 101.31)</td>
<td>TT+TG</td>
<td>2.91 (2.73, 3.1)</td>
</tr>
<tr>
<td>RS609203</td>
<td>SIGLEC1</td>
<td>A/C</td>
<td>CC+CA</td>
<td>95.25 (92.76, 97.74)</td>
<td>CC+CA</td>
<td>2.44 (2.28, 2.6)</td>
</tr>
<tr>
<td>RS3859664</td>
<td>SIGLEC1</td>
<td>C/T</td>
<td>TT+TC</td>
<td>100.28 (98.36, 102.21)</td>
<td>TT+TC</td>
<td>2.83 (2.68, 2.98)</td>
</tr>
<tr>
<td>RS4813636</td>
<td>SIGLEC1</td>
<td>A/G</td>
<td>GG+GA</td>
<td>95.13 (92.56, 97.71)</td>
<td>GG+GA</td>
<td>2.67 (2.54, 2.8)</td>
</tr>
<tr>
<td>RS910652</td>
<td>HSPA12B</td>
<td>A/G</td>
<td>AA</td>
<td>2.89 (2.72, 3.06)</td>
<td>AA</td>
<td>2.89 (2.72, 3.06)</td>
</tr>
</tbody>
</table>

FDR, false discovery rate; GM, geometric mean.

*Common allele is listed first.
However, we acknowledge that we cannot completely eliminate the potential impact of multiple testing on the reliability of our conclusions.

One strength of our study is that we have not used a questionnaire to ascertain asthma severity, but the information from medical records detailing each asthmatic child’s hospital admission due to acute asthma exacerbation. We capitalized on the fact that in this part of Croatia, all asthmatic participants are regularly followed in our asthma clinic. This is the only hospital in the region, and we maintain accurate records of all hospital admission, outpatient appointments and all prescriptions. Such source of information allowed more accurate and precise definition of hospitalisation than studies which relied on questionnaires.

**Interpretation**

Several SNPs in ADAM33, ATRN, GFRA4, SIGLEC1 and HSPA12B were associated with asthma and, amongst asthmatics, with severity of their disease, a number of these only in the context of ETS exposure. ADAM33 encodes a protein which is a member of the transmembrane zinc-dependent matrix metalloproteinases and is involved in cell adhesion, cell fusion, cell signalling and proteolysis (19). Genes in the vicinity of ADAM33 have a role in inflammation (ATRN has several isoforms, some of which are involved in the initial immune cell clustering during inflammatory responses and may regulate chemotactic activity of chemokines (27); SIGLEC1 encodes a member of the immunoglobulin superfamily expressed by macrophages and is involved in mediating cell-to-cell interactions (28); and variants in HSPA12B may confer susceptibility to atherosclerosis (29)). However, it remains plausible that it is other SNPs in LD with the identified SNPs which are causally associated with asthma and abnormalities in lung function. In our study, most SNPs associated with asthma and lung function were found in the introns at the 5′ end of the gene and may be involved in the control of RNA stability and alternative splicing. Studies of alternative splicing of ADAM33 transcripts suggest that the variability in exon usage occurs at the 5′ end of the gene (the metalloprotease and prodomains, corresponding to SNPs rs487377 through rs3918395(30)). Another proposed functional mechanism suggests that variants on the 5′ end of the gene may directly affect catalytic activity and promote angiogenesis and thus be important in airway wall remodelling (31). Although functional assessments were not within the remit of this study, our results are consistent with findings that soluble ADAM33 in bronchial alveolar lavage is increased in asthma and correlates with disease severity and reduced lung function (32). Further studies are needed to elucidate the functional role of these SNPs and molecular mechanisms that may confer asthma susceptibility.

Maternal smoking is a risk factor for reduced lung function and wheezing (33). However, not all exposed children are affected to a similar degree. In our study population, 1/5 of children were exposed to ETS during early life; ETS exposure per se was not a risk factor for asthma, and certain genetic variants in the region were not associated with asthma or lung function. However, potential importance of these variants was uncovered when the early-life ETS exposure was taken into account (for example, carriers of G allele on ATRN SNP rs3848809 had two times higher risk for asthma, but only if they were exposed to ETS in early life, with no effect of genotype in the absence of ETS exposure and no effect of ETS exposure amongst A-allele homozygotes). The first reported interaction between in utero ETS exposure and ADAM33 variants with respect to lung function suggested that ETS exposure was associated with lower lung functions amongst carriers of minor allele in ADAM33 SNPs rs528557 and rs3918396(6). However, two further studies failed to demonstrate any such interactions (7,10). In the current study, the most striking and consistent interaction between genetic variants and ETS exposure was for ADAM33 SNP rs512625 in relation to asthma severity (G-allele homozygotes who were exposed to ETS had markedly higher risk of multiple hospitalisations and had significantly lower FEF_{25} compared with those not exposed, with no effect of ETS exposure amongst carriers of A allele).

In conclusion, we have demonstrated several novel significant interactions between polymorphisms in 20p13-p12 region and early-life ETS exposure with asthma presence and, amongst patients with asthma, a significant association with the severity of their disease, confirming that 20p13-p12 is an important asthma susceptibility locus.

**Funding**

JP Moulton Charitable Foundation; BKB and MB supported by a short-term EAACI Fellowship.

**References**


---

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

- **Table E1.** SNPs selected for genotyping on ATRN gene.
- **Table E2.** SNPs selected for genotyping on GFR4 gene.
- **Table E3.** SNPs selected for genotyping on ADAM33 gene.
- **Table E4.** SNPs selected for genotyping on SIGLEC1 gene.
- **Table E5.** SNPs selected for genotyping on HSPA12B gene.
- **Table E6.** Association between genetic variants in the region 20p13-p12 and lung function measures amongst asthmatic children.
- **Table E7.** Significant interactions between genetic variants in 20p13-p12 and early-life environmental tobacco smoke exposure in relation to asthma.
- **Table E8.** Significant interactions between genetic variants in 20p13-p12 and early-life ETS exposure in relation to lung function amongst children with asthma.

Figure E1. Linkage disequilibrium plot for analysed SNPs in region 20p13-12p showing pairwise r² values.

Figure E2. Interaction between genetic variant in ATRN and early-life ETS exposure in relation to asthma: Early-life ETS exposure significantly increases the risk of asthma amongst carriers of G allele on rs3848809, with no effect of ETS exposure on asthma risk amongst A allele homozygotes.

Figure E3. Interaction between genetic variant in ADAM33 and early-life ETS exposure in relation to FEF50. Homozygotes for G allele on rs512625 have lower FEF50 if they are exposed to ETS, with no effect of ETS exposure amongst carriers of A allele.